RT Journal Article
SR Electronic
T1 Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3921
OP 3932
VO 37
IS 7
A1 YONEHIRO KANEMURA
A1 MIHO SUMIDA
A1 YOSHIKO OKITA
A1 EMA YOSHIOKA
A1 ATSUYO YAMAMOTO
A1 DAISUKE KANEMATSU
A1 YUKAKO HANDA
A1 HAYATO FUKUSUMI
A1 YUI INAZAWA
A1 AI TAKADA
A1 MASAHIRO NONAKA
A1 SHIN NAKAJIMA
A1 KANJI MORI
A1 SHIGENORI GOTO
A1 TAKASHI KAMIGAKI
A1 TOMOKO SHOFUDA
A1 SHUSUKE MORIUCHI
A1 MAMI YAMASAKI
YR 2017
UL http://ar.iiarjournals.org/content/37/7/3921.abstract
AB In this clinical study, we investigated the safety and clinical usefulness of systemic adoptive immunotherapy using autologous lymphokine-activated αβ T-cells (αβ T-cells), combined with standard therapies, in patients with malignant brain tumors. Twenty-three patients with different malignant brain tumors, consisting of 14 treated with temozolomide (TMZ group) and 9 treated without temozolomide (non-TMZ group), received systemic intravenous injections of αβ T-cells (mean=10.4 injections/patient for the TMZ group, and 4.78 for the non-TMZ group). No significant adverse effects associated with the αβ T-cell injection were observed, and the total lymphocyte count (TLC) improved significantly in the TMZ group after five injections. Furthermore, CD8-positive or T-cell receptor V gamma -positive cells were increased with TLC in three patients with glioblastoma multiforme. These findings suggest that systemic αβ T-cell immunotherapy is well tolerated, and may help restore an impaired and imbalanced T-cell immune status, and temozolomide- and/or radiotherapy-induced lymphopenia. Future prospective study is needed to clarify the clinical merits of this immunotherapy.